|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7580 EUR | -0.52% |
|
-0.26% | -28.36% |
| 07-01 | Amoéba Receives Marketing Authorization For Biofungicide AXPERA In France | CI |
| 06-30 | Amoéba gains from marketing authorization in France |  |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- ALMIB Stock
- Consensus Amoéba
- Estimates Revisions
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
